Abstract

THE USE OF TICAGRELOR TO PREVENT SEPSIS-INDUCED COAGULOPATHY IN COVID-19

Pramod Sarraf* and Chandanam Sreedhar

ABSTRACT

In December 2019, a novel coronavirus, now named SARS-CoV-2, caused a series of acute atypical respiratory diseases in Wuhan, Hubei Province, China. The disease caused by this virus was termed COVID-19. The outbreak of SARS-CoV-2 was considered to have originally started via a zoonotic transmission associated with the seafood market in Wuhan, China. The virus is transmittable between humans and has caused a pandemic worldwide. The number of death tolls continues to rise and a large number of countries have been forced to do social distancing and lockdown. The lack of targeted therapy continues to be a problem. Epidemiological studies showed that elder patients were more susceptible to severe diseases, while children tend to have milder symptoms. COVID-19 is also associated with sepsis-induced coagulopathy (SIC) leading to disseminated intravascular coagulation (DIC). Here I reviewed the current knowledge about the use of Ticagrelor to prevent sepsis-induced coagulopathy in COVID-19.

Keywords: COVID-19 Sepsis-induced coagulopathy, P2Y12 inhibitor, Ticagrelor, low molecular weight heparin